Bio­gen, Io­n­is win FDA OK for spinal mus­cu­lar at­ro­phy drug Spin­raza

Bio­gen $BI­IB and Io­n­is $IONS got an ear­ly Christ­mas present Fri­day evening as the FDA an­nounced that it had pro­vid­ed an ac­cel­er­at­ed ap­proval for Spin­raza (nusin­ersen), their new drug — and the first — for rare cas­es of spinal mus­cu­lar at­ro­phy.

Peak sales es­ti­mates hov­er around $2 bil­lion, with some of the new es­ti­mates com­ing in over $3 bil­lion by 2026.

“Our pre­vi­ous fore­cast in­clud­ed sales of $75mm in 2017 grow­ing to $2.8bn by 2026,” not­ed Leerink’s Ge­of­frey Porges in ear­ly No­vem­ber, with the ar­rival of more Phase III da­ta. “We now as­sume a launch in Q1 2017 from Q2 2017 pre­vi­ous­ly and our cur­rent fore­cast is for sales of $92mm in 2017 in­creas­ing to $1.56bn by 2020 and then $3.2bn by 2026.”

Bio­gen says that it will be ready to ship the drug in a week.

Shares of Io­n­is shot up 10% and Bio­gen saw its stock climb 2% on the news.

The ap­proval comes a lit­tle less than two months af­ter re­searchers post­ed a fresh round of promis­ing da­ta on the drug. Us­ing the Ham­mer­smith Func­tion­al Mo­tor Scale Ex­pand­ed re­port card for pa­tients’ mo­tor func­tions, the drug arm wit­nessed a mean 4.0 im­prove­ment on scores while the place­bo arm dropped by 1.9 points, a 5.9 point over­all spread in the drug’s fa­vor.

Io­n­is CEO Stan­ley Crooke

Both com­pa­nies bad­ly need­ed this win af­ter a year of up­heavals. The ap­proval will help set the stage for Bio­gen’s new CEO, Michel Vounatsos, to take the helm. Io­n­is, mean­while, can boast of a year-end vic­to­ry af­ter set­backs in the clin­ic. And an­a­lysts were im­pressed by the broad la­bel ap­plied by the FDA.

“La­bel­ing is not re­strict­ed to any spe­cif­ic SMA sub­type, in­di­cat­ing that it will like­ly be broad­ly pre­scribed for type 1, 2, and 3 pa­tients and while the epi­demi­ol­o­gy in SMA is not en­tire­ly de­fin­i­tive, a la­bel mak­ing the drug avail­able to all pa­tient types rep­re­sents sig­nif­i­cant ex­pan­sion po­ten­tial to the ini­tial mar­ket op­por­tu­ni­ty (though giv­en the un­met need in SMA, this pos­i­tive de­vel­op­ment is not en­tire­ly un­sur­pris­ing),” notes Jef­feries Bri­an Abra­hams.

The ap­proval al­so comes with a rare dis­ease pri­or­i­ty vouch­er, which can be used to ac­cel­er­ate re­view of an­oth­er pro­gram, or sold on the open mar­ket.

“There has been a long-stand­ing need for a treat­ment for spinal mus­cu­lar at­ro­phy, the most com­mon ge­net­ic cause of death in in­fants, and a dis­ease that can af­fect peo­ple at any stage of life,” said Bil­ly Dunn, MD, di­rec­tor of the Di­vi­sion of Neu­rol­o­gy Prod­ucts in the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search. “As shown by our sug­ges­tion to the spon­sor to an­a­lyze the re­sults of the study ear­li­er than planned, the FDA is com­mit­ted to as­sist­ing with the de­vel­op­ment and ap­proval of safe and ef­fec­tive drugs for rare dis­eases and we worked hard to re­view this ap­pli­ca­tion quick­ly; we could not be more pleased to have the first ap­proved treat­ment for this de­bil­i­tat­ing dis­ease.”

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.